We are pleased to announce the appointment of daniel verstappen as VP Quality assurance and regulatory affairs
– Brings almost three decades of leadership experience in the MedTech space
– Helped drive the transformation of Philip Morris International into a Life Science company in his role as part of the management team
– Has strong expertise in Quality and Regulatory Leadership
BELGIUM – Ghent, December 21, 2021 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, is pleased to announce the appointment of Daniël Verstappen as VP Quality Assurance and Regulatory Affairs.
Daniël has amassed almost 30 years’ experience working for medical device companies. Most recently as Global VP, Quality, Regulatory Affairs and Standard Management at Philip Morris International, where he led a team of approximately 2,650 employees, 13 direct report and 54 production sites worldwide. Phillip Morris is currently transforming into a life science company and whilst there Daniël was part of the management team that created the vision and developed the transformation strategy.
Daniël’s expertise lies firmly in providing Quality and Regulatory Assurance leadership, having had a senior leadership position in Quality and Regulatory Affairs at Nobel Biocare, GE Healthcare International and Philips Healthcare. His experience during these positions includes determining Regulatory and Quality strategy and driving excellence in both operations, whilst collaborating with the CEO to drive organizational vision.
Daniël holds a Bachelor’s degree in Nursing.
DANAË DELBEKE, CEO, INVENTOR AND CO-FOUNDER OF INDIGO DIABETES, COMMENTED:
“We’re delighted to welcome Daniël as VP Quality Assurance and Regulatory Affairs to the Indigo team. His deep experience in driving organisational vision and operating strategy to strengthen the businesses of MedTech companies will be vital as we continue developing our subcutaneous continuous multi metabolite monitoring (‘CMM’) device. Daniël’s appointment underscores the momentum at which we are evolving the business to fulfil our ambition of making our CMM device commercially available to people living with diabetes as quickly as possible.”
DANIËL VERSTAPPEN, VP QUALITY ASSURANCE AND REGULATORY AFFAIRS OF INDIGO DIABETES, COMMENTED:
“I am thrilled to be joining the Indigo team at such a pivotal time in its business development. I look forward to driving Regulatory and Quality Excellence to facilitate transforming diabetes management by bringing the company’s innovative CMM device to people living with diabetes.”